OpGen is a precision medicine company engaged in molecular diagnostics and informatics. Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, Co. is developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information about life threatening infections. Co.'s existing product portfolio includes Unyvero, Acuitas Antimicrobial Resistance (AMR) Gene Panel, and the ARES Technology Platform including ARES reference database on antimicrobial resistance, Next Generation Sequencing technology and Artificial Intelligence-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction. The OPGN YTD return is shown above.
The YTD Return on the OPGN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether OPGN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OPGN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|